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OBJECTIVES: To investigate the economic impact of a device
for automating the preparation of sterile solutions in the Mount
Sinai Hospital Pharmacy. METHODS: The Gri-ﬁll system (G-S)
uses sterile ﬁltration and a documented ﬁlter integrity test for
each unit of sterile solution prepared. The present study exam-
ined the economic impact of the G-S in preparing 3 pain 
management solutions and 4 total parenteral nutrition (TPN)
solutions. Costs were categorized in terms of staff time, drug,
and disposable costs for the G-S versus the usual manual process.
For each product type, a minimum of 30 units were prepared
using each process. Material costs were calculated using Average
Wholesale Prices (AWP) of drugs and disposables; staff costs
were based on hospital administrative costs for pharmacist and
technician time. RESULTS: The number of units prepared for
each solution ranged from 24 to 129. Batch size was consider-
ably larger with the G-S (mean of 30.7 units per batch with G-
S, 4.9 units with the manual system). Production cost per unit
was lower with the G-S for 5 of the 7 solutions studied. Main
differences between the two systems were in terms of disposable
costs, which were proportionally greater with the G-S (mean of
$9.54 per unit with G-S compared to $6.05 manual, for all solu-
tions), and staff costs, which were less with the G-S (mean of
$0.82 per unit compared to $3.84 for the manual system, all
solutions). CONCLUSIONS: The G-S produced cost savings for
most of the solutions studied. The size of savings is dependent
primarily on solution mix and batch size.
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OBJECTIVES: Two approaches are available for contrast agent
injection in Multislice CT: single-patient (SiPA) and multi-patient
(MuPA): The former requires one set of devices for 1 patient, the
latter uses one set for two to four patients. The objective is to
quantify the beneﬁt in terms of time and cost saving between the
two approaches. METHODS: The study was performed in two
Spanish hospitals. Assessment was based on three measurements:
time spent carrying out the injection, quantity of devices used,
volumes of XENETIX® ﬁlling the syringe and injected to
patients. The costs of devices and XENETIX® were taken from
hospital bills. Times collected were linked to costs through an
average hourly cost of nurses and/or radiodiagnostic specialists
involved. A sensitivity analysis was performed to determine in
which proportions of 2-, 3-, or 4-patient vials the MuPA is dom-
inant. RESULTS: 209 patients were included in two groups. The
durations of manipulation are favourable to the MuPA (121 vs.
151sec/patient) but patients were not identically distributed: the
ﬁrst patients’ durations in the MuPA are higher than the later
ones. So a sensitivity analysis was performed by varying the pro-
portion of vials with 2,3,4 patients. These simulations reveal that
the MuPA is dominant in nearly all cases (except when the rate
of patients treated with a 2-patient vial is superior to 20%, which
is not realistic). In a sample of 200 patients the SiPA and the
MuPA entails mean total costs of €11,972 and €10,931 respec-
tively (p < 0.0001 Wald-test) with proportions based on the col-
lected sample (91.4%, 5.7% and 2.9% of vials with 3, 2 and 4
patients respectively). CONCLUSIONS: The descriptive and sen-
sitivity analysis proves statistically that the MuPA is the more
time- and cost-saving and deserves to be supported.
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OBJECTIVE: Severe blunt trauma injuries are known to affect
more than 12,000 individuals in the UK (UK) each year, the
majority of whom require very intensive and expensive emer-
gency care. A number of studies have estimated the direct and
indirect cost of severe trauma injuries in different countries. The
objective of this study is to provide an estimate of the direct
medical cost of severe blunt trauma in the UK. METHODS: A
bottom-up costing exercise was undertaken to estimate the direct
medical cost of a typical severe blunt trauma patient involved in
a motor vehicle trafﬁc accident from the perspective of the 
UK NHS. The typical severe blunt trauma patient used in the
analysis was adapted from previously published literature to be
representative of patients presenting at UK trauma centers. UK-
speciﬁc unit costs were applied to the different items of resource
use identiﬁed in order to estimate the direct medical cost of a
severe blunt trauma patient in the UK. RESULTS: The estimated
direct medical cost of a severe blunt trauma patient in the UK is
£48,813. The main cost drivers are ICU stay (56%) and surgi-
cal intervention (32%). This estimate is similar to those reported
in the literature. The incidence of severe trauma in UK is esti-
mated to be four per one million per week (approximately
12,000 per year). This indicates that the total direct cost to the
UK NHS of severe trauma is around £0.6 billion per year. Given
that published studies suggest that the direct medical costs of
trauma represent about 25% of the total cost, the total cost of
trauma in the UK would be around 2.4 billion per year. CON-
CLUSIONS: The direct medical cost of trauma represents a sub-
stantial economic burden to society. Initiatives that reduce this
burden (e.g. prevention, treatment) are welcomed.
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OBJECTIVES: To describe the development of drug wholesale
price indices in Finland in 1980–2004. METHODS: Price indices
covering study period (The Helsinki Research Institute for Busi-
ness Administration [1980–1990], IMS [1991–1994] and Statis-
tics Finland [1995–2004]) were merged into two index clusters
(1980 = 100 and 1990 = 100). The latter enables more precise
classiﬁcation according to reimbursement categories. Real price
indices were produced by adjusting nominal indices with Con-
sumer Price Index (CPI, Statistics Finland) and its sub-index
Consumer Price Index for Health Care (CPI—H, Statistics
Finland). RESULTS: In 2004, the index (1980 = 100) for all
drugs was 167 (CPI adjusted 65; CPI—H adjusted 33) and for
basic refund category 141 (55; 28), respectively. The respective
ﬁgures in 1990 = 100 index were: all drugs 107 (84; 60), pre-
scription based 101 (79; 57), reimbursed 96 (75; 54), Basic
Refund (“50%”) 96 (76; 54), Lower Special Refund (“75%”)
91 (71; 51) and Higher Special Refund (“100%”) 102 (80; 58).
CONCLUSIONS: Nominal drug wholesale prices have increased
